Ireland’s Croí Laighean Selects Temenos SaaS to Create Credit Union of the Future
2.3.2021 10:30:00 EET | Business Wire | Press release
Temenos (SIX: TEMN), the banking software company, today announced that Croí Laighean Credit Union has selected Temenos front-to-back Software-as-a-Service (SaaS) to transform its digital banking. This strategic move from a legacy, on premise system to a community banking solution powered by Temenos SaaS will ensure that Croí Laighean has the technology it needs now and into the future to compete on a level playing field with the big banks and fintech challengers. For Croí Laighean, a strong community presence and the best in digital banking is a winning combination that will help the credit union to differentiate with a service that appeals to members and supports growth.
Paul Kennedy, CEO, Croí Laighean, commented: “We are delighted to partner with Temenos to transform our digital banking capability. The Temenos platform puts us on a par technologically with the world’s biggest banks. The move from on premise software to Temenos SaaS was a strategic decision that will set us up for success long into the future. We are already well on the way to transitioning to the new system and look forward to launching new products and experiences for the benefit of our members this year.”
David Macdonald, President of Europe, Temenos, said: “We are proud to welcome Croí Laighean to the growing community of credit unions choosing Temenos SaaS to accelerate their digital ambitions and attract a new generation of members. The flexible deployment capabilities of our community banking solution is ideal for the credit unions in Ireland, delivering the opportunity for a fully managed service that is secure, resilient and future-proof. This is a big step forward for Croí Laighean and the start of an exciting journey for its members.”
Hosted on Microsoft Azure in Microsoft’s Dublin data center, the service is already in use by a number of other credit unions in Ireland, including Capital Credit Union, Credit Union Plus and Tullamore Credit Union.
Temenos’ community banking solution offers pre-packaged, front-to-back credit union products, processes and channels, all built on modern cloud-native and API-first technology. It gives Croí Laighean the capability to offer outstanding digital member experiences, bring new products to market faster and achieve efficiencies through increased automation and digitization of processes. Delivered as SaaS, Croí Laighean is always up-to-date with the latest in digital banking technology without the cost and risk of maintaining on premises systems.
The Covid-19 pandemic has accelerated the shift towards digital banking and Temenos SaaS will help Croí Laighean to provide more member-friendly services, more efficiently, via mobile app on online. Before the pandemic, 60% of Croí Laighean members’ weekly transactions were in branch compared to 40% via digital channels. By the start of 2021, the proportion of weekly transactions via digital had increased to over 80% and this is trend is only expected to continue.
– Ends –
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 1.2 billion banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com.
About us
Croí Laighean Credit Union now has over 38,000 members in our common bond which stretches from Rhode, Co. Offaly in the West to Leixlip, Co. Kildare in the East. We now have 7 branches: Edenderry, Coill Dubh, Clane, Leixlip, Allenwood, Carbury and Prosperous.
For more information, please visit www.clcu.ie
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210301005641/en/
Contact information
Media Contacts
Jessica Wolfe & Scott Rowe
Temenos Global Public Relations
Tel: +1 610 232 2793 & +44 20 7423 3857
Email : press@temenos.com
Alistair Kellie & Andrew Adie
Newgate Communications on behalf of Temenos
Tel: +44 20 7680 6550
Email:
allnewgatetemenos@newgatecomms.com
Croí Laighean Credit Union
Martin Fitzgerald, Community Relations
087 979 8300
martin.fitzgerald@clcu.ie
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom